Početna stranicaBIOCON • NSE
add
Biocon Ltd
Preth. zaklj. cijena
364,45 ₹
Dnevni raspon
366,50 ₹ - 373,65 ₹
Godišnji raspon
244,55 ₹ - 404,70 ₹
Tržišna kapitalizacija
446,29 mlr. INR
Prosječna količina
5,56 mil.
P/E omjer
55,43
Prinos dividende
0,13 %
Glavno tržište vrijednosnica
NSE
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (INR) | pro 2024.info | Godišnja promjena |
|---|---|---|
Prihod | 38,56 mlr. | −2,47 % |
Operativni troškovi | 21,36 mlr. | −3,34 % |
Neto dohodak | 251,00 mil. | −96,20 % |
Neto profitabilnost | 0,65 | −96,11 % |
Zarada po dionici | 0,13 | −97,54 % |
EBITDA | 7,42 mlr. | −5,55 % |
Efektivna porezna stopa | 47,98 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (INR) | pro 2024.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | — | — |
Ukupna imovina | — | — |
Ukupne obveze | — | — |
Ukupni kapital | — | — |
Dionice u optjecaju | 1,20 mlr. | — |
Cijena prema knjigovodstvenoj vrijednosti | — | — |
Povrat imovine | — | — |
Povrat kapitala | 2,08 % | — |
Tok novca
Neto promjena novca
| (INR) | pro 2024.info | Godišnja promjena |
|---|---|---|
Neto dohodak | 251,00 mil. | −96,20 % |
Gotovina od poslovanja | — | — |
Gotovina iz ulaganja | — | — |
Gotovina iz financiranja | — | — |
Neto promjena novca | — | — |
Slobodan tok novca | — | — |
Više
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, India. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
Glavni izvršni direktor
Osnovano
1978
Sjedište
Web-lokacija
Zaposlenici
16.315
